Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$162.5M
11M shares
52-week range
$4.86 – $17.40
77% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
5.93%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.1K | $1.6K | $988.1K | $15.2M | $10.0K | $555 | $2.3M | $42.0K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $13.1K | $1.6K | $988.1K | $15.2M | $10.0K | $555 | $2.3M | $42.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $9.8M | $6.5M | $9.5M | $14.5M | $20.2M | $15.6M | $17.4M | $7.3M |
| Operating income | −$12.5M | −$8.4M | −$12.2M | −$6.4M | −$25.4M | −$24.1M | −$28.5M | −$14.2M |
| EBITDA | −$10.8M | −$7.7M | −$11.1M | −$5.1M | −$23.5M | −$22.3M | −$26.6M | −$13.3M |
| Net income | −$6.0M | −$10.3M | −$12.5M | −$8.4M | −$25.0M | −$20.5M | −$26.8M | −$20.7M |
| Net margin | -46071.1% | -656230.0% | -1261.7% | -55.5% | -250140.0% | -3687419.8% | -1160.2% | -49290.5% |
| EPS (diluted) | -59.80 | -85.60 | -80.00 | -35.80 | -95.00 | -55.00 | -55.00 | -18.90 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $178413 | $-1.00 | $-1.35–$-0.66 | 1 |
| 2027 | $145000 | $-1.51 | $-2.03–$-1.00 | 1 |
| 2028 | $5M | $-1.96 | $-2.63–$-1.29 | 1 |
| 2029 | $43M | $0.17 | $0.11–$0.23 | 1 |
Forward consensus · source: Financial Modeling Prep
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
www.kaziatherapeutics.comNo one on the platform currently holds KZIA.
No tracked institution reports a position in KZIA as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-04-17 | 1-for-5reverse |
| 2024-10-28 | 1-for-10reverse |
| 2017-07-14 | 1-for-4reverse |
No one on the platform has traded KZIA yet.
| $2M |
| — |
| GRIGRI Bio, Inc. | $1.86 | +2.20% | $167088 | — |
| INMInMed Pharmaceuticals Inc. | $1.57 | +1.95% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 3827.2× sales vs its 179.5× historical median P/S.
Fair value ≈ $0.68 · price $14.46 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $KZIA and $SMX worth bookmarking
View on StockTwits ↗$KZIA Nobody would question an immediate NPV of one billion dollars, for a standout positive meeting TYPE C meet with the FDA soon. That represents a 600% SP gap. This is a highly impactful situation, completely not understand by the market. Significant and highly relevant news from the last week or do. A must to google for more detail. The FDA dramatically reversed its stance on AMT-130, an experimental gene therapy by UniQure that slows Huntington's disease progression. After initially demanding a new trial, the FDA agreed to accept existing three-year data to support an application for accelerated approval in the U.S.This sudden U-turn means the regulatory process is back on track. Accelerated approval is now likely to be forthcoming from the FDA, in this rare brain disease.
View on StockTwits ↗$KZIA Pete.. I know I said it the other day but my daily double with $SLS is warranting a big smile.. all good pal .. ….catch ya next week ..
View on StockTwits ↗$KZIA only Monday and Tuesday left in Q2 .. Q3 starts Wednesday mmm it’s been quiet for a while without any news mmmm
View on StockTwits ↗$KZIA Tax loss selling from Australia - most of which would be over now. The early clinical results are unprecedented, with really what is profound tumor destruction and clear biological disruption of cancer spread. The early trial data is supposed by scientific mechanisms and understanding of how the paxalisib drug combination study works. Hopelessly undervalued . An expanded access protocol, with advanced metastatic TNBC patient achieved a confirmed immune-complete metabolic response (iCR). This patient saw an 86% tumor burden reduction in just three weeks, leading to a 100% complete disappearance of all lesions, confirmed by imaging scans. An outstanding share price buying opportunity, which exceeds all opportunities elsewhere.
View on StockTwits ↗$KZIA question for all. Where will we be at end of 2026? 1. Partnership 2. Buy out 3. On our own trying to grow and excel Stock Price Prediction?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.